Prestige Consumer Healthcare (PBH): יחס שווי שוק לרווח וקצב צמיחה
Prestige Consumer Healthcare (PBH) maintains a portfolio of recognizable OTC brands and strict FDA oversight that create significant barriers to entry for competitors. A comparison of P/E ratios and growth rates demonstrates valuation dynamics where 1.28 represents the latest level. Secured positions in the hygiene segment guarantee financial stability, while the high counter-cyclical demand for basic medications ensures a reliable cash flow even during GDP declines.
%20%D7%99%D7%97%D7%A1%20%D7%9E%D7%97%D7%99%D7%A8%20%D7%9C%D7%A8%D7%95%D7%95%D7%97%20%D7%9C%D7%A7%D7%A6%D7%91%20%D7%A6%D7%9E%D7%99%D7%97%D7%94&width=1200&height=400&colorIndex=0&v=mwbxec28.yq-7cu2wow&start=20220704&end=20261111&filename=GURU_Markets_-_PBH_-_Prestige-Consumer-Healthcare_-_PriceEarnings-to-Growth-Ratio "מקדם החזר מותאם קצב צמיחה: prestigebrands.com (PBH) עבור 04.07.2022 - 11.11.2026 | 👁️GURU.Markets👁️")
Prestige Consumer Healthcare (PBH) - פילוחי מדדים ודוחות פיננסיים
The PEG ratio measures the cost of a single unit of earnings growth, where the value of 1.28 determines the degree of an asset's undervaluation relative to its dynamics. Analyzing the undervalued "rockets" filter via PEG allows for the elimination of market noise, confirming that the resilience of Prestige Consumer Healthcare niche brands and customer loyalty create a genuine foundation for capitalization growth.
